·前   言
·公   司
·发展历史
·新闻
·观念体系
·管理和策略
·生产厂房
·产品和种类
·产品市场
·员   工
·质   量
·产品的安全性
·环   境
·联系方式
·ENGLISH
                             
  当前主题共2下一页
     




The product portfolio of Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd consists of vaccines against Influenza (Split Virion), inactivated, Haemorrhagic Fever with Renal Syndrome (HFRS) and Japanese

 


Encephalitis (JEV). Influenza vaccine is produced in a dedicated workshop while HFRS and JEV vaccines are produced on a campaign basis.

With a fast growing market, newly completed production, quality control and R&D facilities, and several other new vaccines in the pipeline, the Company expects to see a steady business growth in the next few years.

We have a promising vaccine pipeline, with 1 project in clinical phase 1 and 2 projects in clinical phase 3.

Furthermore we have promising vaccines in our current development portfolio and are keen on cooperation for diverse other vaccines.

 


  Vaccines in development -正在研发的疫苗

Avian Flu - 禽流感
Pneumococcal Polysaccharide Vaccine (PPV) - 肺炎球菌多糖疫苗
Haemophilus influenza type B (HIB) - B型流感嗜血杆菌疫苗

当前主题共2下一页
 
浙江天元生物药业股份有限公司 版权所有(C)2007,网络支持 中国医药网 生意宝